Celldex's CDX-301 Safely Mobilizes Hematopoietic Cells in Phase 1 Study

Celldex Therapeutics, Inc. (NASDAQ: CLDX ) announced positive results from a Phase 1 multi-dose study of CDX-301 (FMS-like tyrosine kinase-3 ligand) demonstrating that CDX-301 was well-tolerated and can safely and effectively mobilize hematopoietic cell populations in healthy volunteers. The data support future development of CDX-301 in a number of indications, including hematopoietic stem cell